Back to CVE records
Medium 4.3Published Jun 1, 2026

CVE-2026-28511eLabFTW is an open source electronic lab notebook.

Updated under an hour ago ()

Does this affect you?

It affects elabftw. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

eLabFTW is an open source electronic lab notebook. Prior to version 5.4.2, in certain cases, an authenticated user performing a numeric reference/search can return results that include resources the requesting user is not authorized to view. The exposed information is limited (only the title). Attempts to access the underlying protected resource content remain blocked by authorization checks. Version 5.4.2 fixes the issue. # Affected Scope Cross-scope visibility of titles. No confirmed bypass of content-level access controls # Preconditions An authenticated user account No special privileges required beyond standard access # Impact This may enable unauthorized disclosure of sensitive information if confidential data is included in resource titles. Examples could include project names, patient identifiers, or other regulated information embedded in titles.

CVSS
4.3 MEDIUM (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Weakness (CWE)
CWE-200
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Analyzed
Record last updated
Jul 22, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
elabftw elabftw
elabftw:elabftw
before 5.4.2
NVD

References

  • vendor-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.